508 filings
Page 3 of 26
8-K
io1m7y0
23 May 22
Submission of Matters to a Vote of Security Holders
4:31pm
8-K
3bhwi01f
28 Apr 22
Results of Operations and Financial Condition
8:10am
DEFA14A
cwtoas96 0nzzr8j
5 Apr 22
Additional proxy soliciting materials
4:21pm
8-K
gsjdehn p9o5hu
5 Apr 22
Alnylam Announces Retirement of Steven Paul, M.D. from Board of Directors
4:16pm
8-K
vg91jehx3yqs1
4 Apr 22
Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
7:35am
8-K
99fc 9seev7359q
17 Mar 22
Other Events
7:36am
8-K
ld3j87bnv2edz 88g47
10 Feb 22
Results of Operations and Financial Condition
8:10am
8-K
czo9lru3ez f0
10 Jan 22
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates
7:01am
8-K
6igrf9urdlnxuz 7ck
4 Jan 22
Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President
4:16pm
8-K
gx7wr6v60id2130g
20 Dec 21
Departure of Directors or Certain Officers
4:15pm
8-K
g2vb6wtyxt
28 Oct 21
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
8:11am
8-K
2nnl480ikm 4pffxw6aw
8 Sep 21
Departure of Directors or Certain Officers
8:35am
8-K
pzy05j2a
3 Aug 21
Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights
8:10am
8-K
1d41lz1
21 May 21
Submission of Matters to a Vote of Security Holders
4:30pm